{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:30:52Z","timestamp":1792585852976,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","award":["1RO1NS070307"],"award-info":[{"award-number":["1RO1NS070307"]}],"id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","award":["K12 HL083781"],"award-info":[{"award-number":["K12 HL083781"]}],"id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ahj.2016.08.017","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T14:15:26Z","timestamp":1478268926000},"page":"150-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Incidence of severe renal dysfunction among individuals taking warfarin and implications for non\u2013vitamin K oral anticoagulants"],"prefix":"10.1016","volume":"184","author":[{"given":"Christina L.","family":"Fanola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Mooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darae","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Sisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori E.","family":"Henault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorghos","family":"Tripodis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2016.08.017_bb0005","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1182\/blood-2007-11-123711","article-title":"Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based","volume":"111","author":"Levi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2016.08.017_bb0010","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2016.08.017_bb0020","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.08.017_bb0025","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ahj.2016.08.017_bb0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0040","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0045","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0050","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.08.017_bb0055","first-page":"e199","article-title":"AHA\/ACC\/HRS guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.08.017_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ahj.2016.08.017_bb0065","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0070","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ahj.2010.03.027","article-title":"Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC)","volume":"159","author":"Soliman","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2016.08.017_bb0075","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Singer DE for the ATRIA Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"199","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.08.017_bb0080","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2215\/CJN.02400311","article-title":"Warfarin in atrial fibrillation patients with moderate chronic kidney disease","volume":"6","author":"Hart","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0090","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0095","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1161\/CIRCULATIONAHA.113.004013","volume":"128","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2016.08.017_bb0100","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0105","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association practical guide on the use of non\u2013vitamin K anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2016.08.017_bb0110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2016.08.017_bb0115","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.08.017_bb0120","series-title":"Package insert. Pradaxa (dabigatran etexilate)","year":"2010"},{"key":"10.1016\/j.ahj.2016.08.017_bb0125","series-title":"Package insert. Xaralto (rivaroxaban)","year":"2012"},{"key":"10.1016\/j.ahj.2016.08.017_bb0130","series-title":"Package insert. Eliquis (apixaban)","year":"2012"},{"key":"10.1016\/j.ahj.2016.08.017_bb0135","series-title":"Package insert, Savaysa (edoxaban)","year":"2015"},{"key":"10.1016\/j.ahj.2016.08.017_bb0140","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0150","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral direct factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0155","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jcph.541","article-title":"Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study","volume":"55","author":"Jonsson","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0160","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti\u2013factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2016.08.017_bb0165","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2","volume":"4","author":"Diener","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.08.017_bb0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ki.2011.178","article-title":"Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease","volume":"80","author":"Swaminathan","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2016.08.017_bb0175","article-title":"Increased arterial inflammation in individuals with stage 3 chronic kidney disease","volume":"14","author":"Takx","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ahj.2016.08.017_bb0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ckj\/sfu017","article-title":"Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease stages 3 and 4","volume":"7","author":"Kiu Weber","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ahj.2016.08.017_bb0185","first-page":"648","article-title":"Warfarin: to use or not to use in chronic kidney disease patients?","volume":"23","author":"Cozzolino","year":"2010","journal-title":"J Nephrol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0190","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ahj.2016.08.017_bb0195","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"Bohm","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2016.08.017_bb0200","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:58:33Z","timestamp":1757570313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316302551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":40,"alternative-id":["S0002870316302551"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.08.017","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of severe renal dysfunction among individuals taking warfarin and implications for non\u2013vitamin K oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}